Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population‐based cohort of elderly patients with non‐Hodgkin lymphoma

There is a lack of research on ethnic disparities in survival among patients with non‐Hodgkin lymphoma (NHL), although these disparities have been documented for patients with many other tumors.

[1]  L. Clegg,et al.  Patterns of care in a population‐based random sample of patients diagnosed with non‐Hodgkin's lymphoma , 2005, Hematological oncology.

[2]  Xianglin L. Du,et al.  Variations in Chemotherapy and Radiation Therapy in a Large Nationwide and Community-Based Cohort of Elderly Patients With Non-Hodgkin Lymphoma , 2007, American journal of clinical oncology.

[3]  B. Vladeċk,et al.  From the Health Care Financing Administration. , 1995, JAMA.

[4]  M. Abdel-Fattah,et al.  Non-Hodgkin's lymphomas in Alexandria, Egypt; incidence rates and trend study (1995–2004) , 2007, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[5]  J. Kolitz,et al.  Treatment of Aggressive Non‐Hodgkin's Lymphoma in Elderly Patients With Thiotepa, Novantrone (Mitoxantrone), Vincristine, Prednisone (TNOP) , 2001, American journal of clinical oncology.

[6]  F. Erdkamp,et al.  The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates , 2001, Annals of Hematology.

[7]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[8]  T M Grogan,et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[9]  R. Deyo,et al.  ADAPTING A CLINICAL COMORBIDITY USE WITH ICD-g-CM ADMINISTRATIVE INDEX FOR DATABASES , 1992 .

[10]  Beth A Virnig,et al.  Utility of the SEER-Medicare Data to Identify Chemotherapy Use , 2002, Medical care.

[11]  Lawrence Tagg.  Services , 1987, Veterinary Record.

[12]  E. Holly,et al.  Changes in Cancer Registry Coding for Lymphoma Subtypes: Reliability Over Time and Relevance for Surveillance and Study , 2006, Cancer Epidemiology Biomarkers & Prevention.

[13]  P. Allison.  Survival analysis using the SAS system : a practical guide , 1995 .

[14]  John Myhre,et al.  CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. , 2003, Blood.

[15]  A. Neugut,et al.  Outcomes and diffusion of doxorubicin‐based chemotherapy among elderly patients with aggressive non‐Hodgkin lymphoma , 2006, Cancer.

[16]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[17]  E. Holly,et al.  Expert Review of Non-Hodgkin’s Lymphomas in a Population-Based Cancer Registry , 2004, Cancer Epidemiology Biomarkers & Prevention.

[18]  R. Fisher,et al.  New treatment options have changed the survival of patients with follicular lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Weisenburger,et al.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. , 2006, Blood.

[20]  P. Gaulard,et al.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  B. Hankey,et al.  Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. , 1995, Cancer.

[22]  S. Devesa,et al.  Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. , 2000, Journal of the National Cancer Institute.

[23]  L. Kessler,et al.  Potential for Cancer Related Health Services Research Using a Linked Medicare‐Tumor Registry Database , 1993, Medical care.

[24]  M Van Glabbeke,et al.  CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Ayers,et al.  Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J L Warren,et al.  Development of a comorbidity index using physician claims data. , 2000, Journal of clinical epidemiology.

[27]  R. Cartwright,et al.  Increasing incidence and descriptive epidemiology of extranodal non-Hodgkin lymphoma in parts of England and Wales. , 2002, The hematology journal : the official journal of the European Haematology Association.

[28]  R. Fisher,et al.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.

[29]  J. Goodwin,et al.  Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  V. Morrison.  Non-Hodgkin's lymphoma in the elderly. Part 2: treatment of diffuse aggressive lymphomas. , 2007, Oncology.

[31]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[32]  P. Boyle,et al.  Epidemiology of non‐Hodgkin lymphoma in connecticut 1935‐1988 , 1992, Cancer.

[33]  C. Lynch,et al.  Improved survival of follicular lymphoma patients in the United States. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  E. Guadagnoli,et al.  Patient Demographic and Socioeconomic Characteristics in the SEER-Medicare Database: Applications and Limitations , 2002, Medical care.

[35]  J. Jollis,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. , 1993, Journal of clinical epidemiology.

[36]  Deborah Schrag,et al.  Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.

[37]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[38]  Xianglin L. Du,et al.  Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy‐related toxicity , 2005, Cancer.

[39]  J. Goodwin,et al.  Information on radiation treatment in patients with breast cancer: the advantages of the linked medicare and SEER data. Surveillance, Epidemiology and End Results. , 1999, Journal of clinical epidemiology.